# Clinical Effectiveness-Implementation Hybrid Type 2 Study on Home-Delivered Cabenuva for People Living With HIV Who Are Not Retained in Care

> **NCT06062979** · — · UNKNOWN · sponsor: **Whitman-Walker Institute** · enrollment: 180 (estimated)

## Conditions studied

- HIV

## Interventions

- **DRUG:** rilpivirine/cabotegravir

## Key facts

- **NCT ID:** NCT06062979
- **Lead sponsor:** Whitman-Walker Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06062979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06062979, "Clinical Effectiveness-Implementation Hybrid Type 2 Study on Home-Delivered Cabenuva for People Living With HIV Who Are Not Retained in Care". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06062979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*